Jakab Ivett, Németh Bertalan, Elezbawy Baher, Karadayı Melis Almula, Tozan Hakan, Aydın Sabahattin, Shen Jie, Kaló Zoltán
Syreon Research Institute, Budapest, Hungary.
Syreon Middle East, Alexandria, Egypt.
Front Pharmacol. 2020 Aug 14;11:1203. doi: 10.3389/fphar.2020.01203. eCollection 2020.
Multicriteria Decision Analysis (MCDA), a formal decision support framework, has been growing in popularity recently in the field of health care. MCDA can support pricing and reimbursement decisions on the macro level, which is of great importance especially in countries with more limited resources.
The aim of this systematic review was to facilitate the development of future MCDA frameworks, by proposing a set of criteria focusing on the purchasing decisions of single-source innovative pharmaceuticals in upper middle-income countries.
A systematic literature review was conducted on the decision criteria included in value frameworks (VFs) or MCDA tools. Scopus, Medline, databases of universities, websites of Health Technology Assessment Agencies, and other relevant organizations were included in the search. Double title-abstract screening and double full-text review were conducted, and all extracted data were double-checked. A team of researchers performed the merging and selection process of the extracted criteria.
A total of 1,878 articles entered the title and abstract screening. From these, 341 were eligible to the full-text review, and 36 were included in the final data extraction phase. From these articles 394 criteria were extracted in total. After deduplication and clustering, 26 different criteria were identified. After the merging and selection process, a set of 16 general criteria was proposed.
Based on the results of the systematic literature review, a pool of 16 criteria was selected. This can serve as a starting point for constructing MCDA frameworks in upper middle-income countries after careful adaptation to the local context.
多标准决策分析(MCDA)是一种正式的决策支持框架,近年来在医疗保健领域越来越受欢迎。MCDA可以在宏观层面支持定价和报销决策,这在资源较为有限的国家尤为重要。
本系统评价的目的是通过提出一套侧重于中高收入国家单一来源创新药物采购决策的标准,促进未来MCDA框架的发展。
对价值框架(VFs)或MCDA工具中包含的决策标准进行系统的文献综述。搜索范围包括Scopus、Medline、大学数据库、卫生技术评估机构网站及其他相关组织的网站。进行了双标题摘要筛选和双全文审查,所有提取的数据都进行了二次核对。一组研究人员进行了提取标准的合并和选择过程。
共有1878篇文章进入标题和摘要筛选。其中,341篇符合全文审查要求,36篇纳入最终数据提取阶段。从这些文章中总共提取了394条标准。经过去重和聚类,确定了26条不同的标准。经过合并和选择过程,提出了一套16条通用标准。
基于系统文献综述的结果,选择了16条标准。在仔细根据当地情况进行调整后,这可以作为中高收入国家构建MCDA框架的起点。